Sulin Kati, Arvas Mikko, Toivonen Suvi, Haimila Katri, Mättö Jaana, Sareneva Inna, Jernman Riina, Parhamaa Anna, Sainio Susanna
Finnish Red Cross Blood Service, Vantaa, Finland.
Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Vox Sang. 2025 Jul;120(7):708-713. doi: 10.1111/vox.70042. Epub 2025 Apr 29.
Timely identification of pregnancies at risk of severe haemolytic disease of the fetus and newborn (HDFN) requires accurate and reproducible antibody titration. This study aimed to establish a critical titre for the gel microcolumn assay (GMA) corresponding to the critical titre of ≥16 for the conventional tube technique (CTT) and to evaluate GMA's suitability for routine antenatal antibody titration.
Altogether, 147 antenatal plasma samples with clinically significant antibodies were studied, including eight pregnancies requiring intrauterine transfusions (IUTs). Twofold serial dilution titres with CTT were made in parallel with automated GMA. Single-dose red blood cells were used with a concentration of 3.5% for CTT and 0.8% for GMA. The critical titre for GMA was compared with CTT as the gold standard.
GMA titres were on average 2.88 (95% confidence interval [CI]: 2.72-3.05) dilutions higher than CTT titres. At a CTT titre of 16, the sensitivity and specificity of GMA titration were maximum (94%, 95% CI: 81-99 and 92%, 95% CI: 85-96, respectively) at a titre of 128, but one of the eight fetuses (12.5%) requiring IUTs would have been missed. At a GMA titre of ≥64, sensitivity and specificity were 100% (95% CI: 100-100) and 77% (95% CI: 68-84) respectively, but the number of pregnancies requiring clinical monitoring more than doubled (2.5×).
A GMA titre ≥64 could be considered a safe critical value for high-risk assessment. Despite being a fully automated method benefiting the screening laboratory, the additional workload and costs caused by unnecessary monitoring at delivery hospitals were unacceptable.
及时识别有胎儿及新生儿严重溶血病(HDFN)风险的妊娠需要准确且可重复的抗体滴定。本研究旨在确定凝胶微柱分析法(GMA)的临界滴度,使其与传统试管技术(CTT)≥16的临界滴度相对应,并评估GMA用于常规产前抗体滴定的适用性。
共研究了147份具有临床意义抗体的产前血浆样本,其中包括8例需要宫内输血(IUT)的妊娠。采用CTT进行两倍连续稀释滴定,并与自动化GMA并行操作。CTT使用浓度为3.5%的单剂量红细胞,GMA使用浓度为0.8%的单剂量红细胞。将GMA的临界滴度与作为金标准的CTT进行比较。
GMA滴度平均比CTT滴度高2.88倍(95%置信区间[CI]:2.72 - 3.05)。在CTT滴度为16时,GMA滴定的敏感性和特异性在滴度为128时达到最大值(分别为94%,95%CI:81 - 99和92%,95%CI:85 - 96),但8例需要IUT的胎儿中有1例(12.5%)会被漏诊。在GMA滴度≥64时,敏感性和特异性分别为100%(95%CI:100 - 100)和77%(95%CI:68 - 84),但需要临床监测的妊娠数量增加了一倍多(2.5倍)。
GMA滴度≥64可被视为高危评估的安全临界值。尽管GMA是一种使筛查实验室受益的全自动方法,但分娩医院因不必要监测导致的额外工作量和成本是不可接受的。